About Us | Contact

Ellin Berman Investigator

Hematology NPI1083685861
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$26,965.52
from 33 payments in the last 6 years

Total Cash or Cash Equivalent

$18,525.00
from 5 payments in the last 6 years

Total In-kind Items & Services

$8,440.52
from 28 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
09/23/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $2620.00 Details
Payment from Novartis Pharmaceuticals Corporation
Payment Record ID 812607739
10/19/2020 Research In-kind items and services Drug $70.83 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319097
09/18/2020 Research In-kind items and services Drug $70.83 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319089
07/09/2020 Research In-kind items and services Drug $100.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319087
07/09/2020 Research In-kind items and services Drug $100.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319085
06/15/2020 Research In-kind items and services Drug $22.35 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319081
05/20/2020 Research In-kind items and services Drug $427.21 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319079
05/20/2020 Research In-kind items and services Drug $70.83 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319077
03/17/2020 Research In-kind items and services Drug $50.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319069
03/17/2020 Research In-kind items and services Drug $151.66 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319067
02/14/2020 Research In-kind items and services Drug $875.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319061
02/14/2020 Research In-kind items and services Drug $75.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Payment Record ID 721319059
10/26/2019 General (Non-Research) In-kind items and services Food and Beverage $240.60 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Payment Record ID 697411383
10/26/2019 General (Non-Research) Cash or cash equivalent Travel and Lodging $35.00 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Payment Record ID 697379619
10/26/2019 General (Non-Research) In-kind items and services Travel and Lodging $281.37 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Payment Record ID 697379617
10/26/2019 General (Non-Research) Cash or cash equivalent Consulting Fee $8910.00 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Payment Record ID 697379613
10/26/2019 General (Non-Research) In-kind items and services Travel and Lodging $366.60 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Payment Record ID 697379609
10/22/2019 Research In-kind items and services Drug $431.25 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386319
10/22/2019 Research In-kind items and services Drug $290.32 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386313
09/18/2019 Research In-kind items and services Drug $375.00 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386305
05/15/2019 Research In-kind items and services Drug $608.82 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386297
03/25/2019 Research In-kind items and services Drug $517.24 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386288
03/25/2019 Research In-kind items and services Drug $533.33 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386281
02/13/2019 Research In-kind items and services Drug $883.33 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386273
02/13/2019 Research In-kind items and services Drug $324.56 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386261
01/09/2019 Research In-kind items and services Drug $190.26 Details
Payment from Astellas Pharma Global Development
Paymment Research Study A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation
Payment Record ID 641386253
01/15/2018 General (Non-Research) Cash or cash equivalent Consulting Fee $3000.00 Details
Payment from PFIZER INC.
Payment Record ID 610382551
10/02/2017 General (Non-Research) In-kind items and services Food and Beverage $19.38 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504480395
05/05/2017 General (Non-Research) In-kind items and services Food and Beverage $300.55 Details
Payment from Millennium Pharmaceuticals, Inc.
Payment Record ID 492605945
05/05/2017 General (Non-Research) In-kind items and services Travel and Lodging $342.20 Details
Payment from Millennium Pharmaceuticals, Inc.
Payment Record ID 492592509
05/05/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $3960.00 Details
Payment from Millennium Pharmaceuticals, Inc.
Payment Record ID 492592507
05/05/2017 General (Non-Research) In-kind items and services Travel and Lodging $297.00 Details
Payment from Millennium Pharmaceuticals, Inc.
Payment Record ID 492592505
05/05/2017 General (Non-Research) In-kind items and services Travel and Lodging $425.00 Details
Payment from Millennium Pharmaceuticals, Inc.
Payment Record ID 492592503
;